Evidence Hub

Method Development and Method Validation of Phosphodiesterase-5 Inhibitor (PDE5-I) and Anti-Diabetic in Diabetic Nephropathy in Animal Model Using RP-HPLC Method

Pranay M. Uplenchwar, P. Mohite

Research Journal of Pharmacy and Technology, 2025

Abstract

Method Development and Method Validation using RP-HPLC Method For Metformin Hydrochloride (MET), Tadalafil (TAL) In Rat Plasma-Application to The Pharmacokinetic Studies, Metformin hydrochloride (MET) is an oral anti-diabetic drug in the biguanide class for the treatment of type 2 diabetes mellitus. Tadalafil (TAL) is a medication used to treat erectile dysfunction and other conditions. For the pharmacokinetic study of MET and TAL, and we developed a simple and sensitive method for estimating MET and TAL in rat plasma using reverse phase high-performance liquid chromatography (RP-HPLC). The drug samples were extracted using solid phase extraction with a stationary-phase strata-X Cartridges and a 1ml mixture of mobile phase. Chromatographic separation was accomplished on a C18 column using (0.3) Triethyl anime buffer: methanol: acetonitrile (70:05:25 v/v) as mobile phase at a flow rate of 1ml/min and UV detection at 224nm. The retention time of MET. The TAL values were found respectively, with a 15-minute separation time. The developed method underwent validation for accuracy, precision, linearity, and recovery. Linearity studies were found to be acceptable between 0.4 and 6.4 ug/ml. The method was successfully applied to analyze rat plasma samples for pharmacokinetic studies, drug interactions, bioavailability, and bioequivalence.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free